Mathematical modeling as a tool for planning anticancer therapy

European Journal of Pharmacology

Volumn 625, Issue 1-3, 2009, Pages 108-121

  Swierniak, Andrzej ^a   Kimmel, Marek ^a,b   Smieja, Jaroslaw ^a  

^a SILESIAN UNIVERSITY OF TECHNOLOGY   (Poland)

^b Rice University   (United States)

Author keywords

Cell cycle models; Chemotherapy optimization; Mathematical modeling; Pharmacodynamics; Pharmacokinetics

Indexed keywords

BLEOMYCIN; CURACIN A; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROXYUREA; IDARUBICIN; IMATINIB; INTERLEUKIN 21; INTERLEUKIN 3; METHOTREXATE; OXALIPLATIN; PACLITAXEL; TOPOTECAN; VINBLASTINE; VINCRISTINE;

ANTIANGIOGENIC THERAPY; BREAST CANCER; CANCER CELL DESTRUCTION; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INVASION; CANCER RESISTANCE; CANCER THERAPY; CARCINOGENESIS; CELL CYCLE ARREST; CELL CYCLE REGULATION; CHRONIC MYELOID LEUKEMIA; CIRCADIAN RHYTHM; DRUG SPECIFICITY; GENE AMPLIFICATION; HUMAN; LUNG CANCER; MATHEMATICAL MODEL; MULTIDRUG RESISTANCE; NEUROBLASTOMA; NEUTROPENIA; NONHUMAN; OVARY CANCER; PHARMACODYNAMICS; POINT MUTATION; PRIORITY JOURNAL; REVIEW; SYSTEMS BIOLOGY; TREATMENT PLANNING; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; DRUG RESISTANCE, NEOPLASM; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION;

EID: 71749103418     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.08.041     Document Type: Review

References (187)

1. Agur Z. The effect of drug schedule on responsiveness to chemotherapy. Ann. N.Y. Acad. Sci. 504 (1988) 274-277
2. Agur Z., Arnon R., and Schachter B. Reduction of cytotoxicity to normal tissues by new regimens of phase-specific drugs. Math. Biosci. 92 (1988) 1-15
3. Agur Z., Arakelyan L., Daugulis P., and Ginosar Y. Hopf point analysis for angiogenesis models. Discrete Contin. Dyn. Syst. Ser. B 4 (2004) 29-38
4. Alison M.R., and Sarraf C.E. Understanding Cancer-From Basic Science to Clinical Practice (1997), Cambridge Univ Press, New York, NY
5. Andreeff M., Tafuri A., Bettelheim P., Valent P., Estey E., Lemoli R., Goodacre A., Clarkson B., Mandelli F., and Deisseroth A. Cytokinetic resistance in acute leukemia: recombinant human granulocyte colony-stimulating factor, granulocyte macrophage colony-stimulating factor, interleukin-3 and stem cell factor effects in vitro and clinical trials with granulocyte macrophage colony-stimulating factor. In: Hidemann, et al. (Ed). Haematology and Blood Transfusion 34, Acute Leukemias-Pharmacokinetics (1992), Springer-Verlag, Berlin 108-116
6. Arakelyan L., Vainstein V., and Agur Z. A computer algorithm describing the process of vessel formation and maturation, and its use for predicting the effects of antiangiogenic and antimaturation therapy on vascular tumor growth. Angiogenesis 5 (2002) 203-214
7. Arakleyan L., Merbl Y., and Agur Z. Vessel maturation effects on tumor growth: validation of a computer model in implanted human ovarian carcinoma spheroids. Eur. J. Cancer 41 (2005) 159-167
8. Arino O. A survey of structured cell population dynamics. Acta Biotheor. 43 (1995) 3-15
9. Arino O., Bertuzzi A., Gandolfi A., Sanchez E., and Sinisgali C. A model with growth retardation for kinetic heterogeneity of tumor cell populations. Math. Biosci. 206 (2007) 185-199
10. Axelrod D.E., Baggerly K.A., and Kimmel M. Gene amplification by unequal chromatid exchange: probabilistic modeling and analysis of drug resistance data. J. Theor. Biol. 168 (1993) 151-159
11. Baer M.M. Clinical significance of multidrug resistance in AML: Current insights. Clin. Adv. Hematol. Oncol. 3 12 (2005) 910-912
12. Bahrami K., and Kim M. Optimal control of multiplicative control systems arising from cancer therapy. IEEE Trans. Automat Contr. 20 (1975) 537-542
13. Basdevant C., Clairambault J., and Lévi F. Optimisation of time-scheduled regimen for anti-cancer drug infusion. Math. Model. Numer. Anal. 39 6 (2005) 1069-1086
14. Baserga R. The Biology of Cell Reproduction (1985), Harvard University Press, Cambridge, MA
15. Bellman R. Mathematical Methods in Medicine (1983), World Scientific, Singapore
16. Bertuzzi A., Gandolfi A., and Vitelli R. A regularization procedure for estimating cell kinetic parameters from flow-cytometric data. Math. Biosci. 82 (1986) 63-85
17. Bertuzzi A., D'Onfrio A., Fasano A., and Gandolfi A. Modelling cell populations with spatial structure: steady state and treatment-induced evolution of tumour cords. Discrete Contin. Dyn. Syst. Ser. B 4 (2004) 161-186
18. Bischoff J. Approaches to studying cell adhesion and angiogenesis. Trends Cell Biol. 5 (1995) 69-73
19. Bonadonna G., Zambetti M., and Valagussa P. Sequential of alternating Doxorubicin and CMF regimens in breast cancer with more than 3 positive nodes. Ten years results. JAMA 273 (1995) 542-547
20. Brehme M., Hantschel O., Colinge J., Kaupe I., Planyavsky M., Köcher T., Mechtler K., Bennett K.L., and Superti-Furga G. Charting the molecular network of the drug target Bcr-Abl. Proc. Natl. Acad. Sci. U.S.A. 106 18 (2009) 7414-7419
21. Brikci F.B., Ribba J., and Perthame B. An age-and-cyclin-structured cell population model for healthy and tumoral tissues. J. Math. Biol. 57 (2008) 91-110
22. Brown B.W., and Thompson J.R. A rationale for synchrony strategies in chemotherapy. In: Lodwig C. (Ed). Epidemiology (1975), SIAM Publ., Philadelphia 31-48
23. Brown P.C., Beverly S.M., and Schimke R.T. Relationship of amplified dihydrofolate reductase genes to double minute chromosomes in unstably resistant mouse fibroblasts cell lines. Mol. Cell. Biol. 1 12 (1981) 1077-1083
24. Calabresi P., and Schein P.S. Medical Oncology, Basic Principles and Clinical Management of Cancer (1993), Mc Graw-Hill, New York, NY
25. Cappuccio A., Elishmereni M., and Agur Z. Cancer immunotherapy by Interleukin-21: potential treatment strategies evaluated in a mathematical model. Cancer Res. 66 14 (2006) 7293-7300
26. Cappuccio A., Elishmereni M., and Agur Z. Optimization of interleukin-21 immunotherapeutic strategies. J. Theor. Biol. 248 (2007) 259-266
27. Chabner B.A., and Longo D.L. Cancer Chemotherapy and Biotherapy (1996), Lippencott-Raven, Philadelphia
28. Chaplain M.A.J., Ganesh M., and Graham I.G. Spatio-temporal pattern formation on spherical surfaces: numerical simulation and application to solid tumour growth. J. Math. Biol. 42 (2001) 387-423
29. Chaplain M.A., McDougall S.R., and Anderson A.R. Mathematical modeling of tumor-induced angiogenesis. Annu. Rev. Biomed. Eng. 8 (2006) 233-257
30. Chappell M.J., Evans N.D., Errington R.J., Khan I.A., Campbell L., Ali R., Godfrey K.R., and Smith P.J. A coupled drug kinetics-cell cycle model to analyse the response of human cells to intervention by topotecan. Comput. Methods Programs Biomed. 89 2 (2008) 169-178
31. Clairambault J., Michel P., and Perthame B. Circadian rhythm and tumour growth. C.R. Math. Acad. Sci. Paris 342 1 (2006) 17-22
32. Clare S.E., Nahlis F., and Panetta J.C. Molecular biology of breast cancer metastasis. The use of mathematical models to determine relapse and to predict response to chemotherapy in breast cancer. Breast Cancer Res. 2 (2000) 396-399
33. Cohen S.M., and Kaufman H.L. Combination cytokine therapy. In: Caligiuri M.A., and Lotze M.T. (Eds). Cytokines in the Genesis and Treatment of Cancers (2007), Humana Press, Totowa, NJ 373-398
34. Cojocaru L., and Agur Z. A theoretical analysis of interval drug design for cell-cycle-phase-specific drugs. Math. Biosci. 109 (1992) 85-97
35. Coldman A.J., and Goldie J.H. A model for the resistance of tumor cells to cancer chemotherapeutic agents. Math. Biosci. 65 (1983) 291-307
36. Coldman A.J., and Goldie J.H. A stochastic model for the origin and treatment of tumors containing drug-resistant cells. Bull. Math. Biol. 48 (1986) 279-292
37. Coldman A.J., Goldie J.H., and Ng V. The effect of cellular differentiation on the development of permanent drug resistance. Math. Biosci. 74 (1985) 177-198
38. Collins M.J., and Dedrick R.L. Pharmacokinematics of anticancer drugs. In: Chabner B.A. (Ed). Pharmacologic Principles of Cancer Treatment (1982), Saunders, Philadelphia 77-99
39. Coly L.P., Van Bekkum D.W., and Hagenbeek A. Enhanced tumor load reduction after chemotherapy induced recruitment and synchronization in a slowly growing rat leukemia model (BNML) for human acute myelonic leukemia. Leukemia Res. 8 (1984) 953-963
40. D'Amato R.J., Loughnan M.S., Flynn E., and Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 4082-4085
41. D'Onofrio A., and Gandolfi A. Tumor eradication by antiangiogenic therapy: analysis and extensions of the model by Hahnfeldt et al. (1999). Math. Biosci. 191 2 (2004) 159-184
42. Davis S., and Yancopoulos G.D. The angio-poietins: Yin and Yang in angiogenesis. Curr. Top. Microbiol. Immunol. 237 (1999) 173-185
43. Denekamp J. Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br. J. Radiol. 66 (1993) 181-196
44. Dibrov B.F., Zhabotinsky A.M., Neyfakh Y.A., Orlova M.P., and Churikova L.I. Optimal scheduling for cell synchronization by cycle-phase-specific blockers. Math. Biosci. 66 (1983) 167-185
45. Dibrov B.F., Zhabotinsky A.M., Neyfakh Y.A., Orlova M.P., and Churikova L.I. Mathematical model of cancer chemotherapy. Periodic schedules of phase-specific cytotoxic-agent administration increasing the selectivity of therapy. Math. Biosci. 73 (1985) 1-31
46. Doherty M.M., and Michael M. Tumoral drug metabolism: perspectives and therapeutic implications. Curr. Drug Metab. 4 (2003) 131-149
47. Dong F., Hoefsloot L.H., Schelen A.M., Broeders C.A., Meijer Y., Veerman A.J., Touw I.P., and Lowenberg B. Identification of a nonsense mutation in the granulocyte-colony-stimulating factor receptor in severe congenital neutropenia. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 4480-4484
48. Dong F., Brynes R.K., Tidow N., Welte K., Lowenberg B., and Touw I.P. Mutations in the gene for the granulocyte colony-stimulating-factor receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia. N. Engl. J. Med. 333 (1995) 487-493
49. Dong F., van Paassen M., van Buitenen C., Hoefsloot L.H., Lowenberg B., and Touw I.P. A point mutation in the granulocyte colony-stimulating factor receptor (G-CSF-R) gene in a case of acute myeloid leukemia results in the overexpression of a novel G-CSF-R isoform. Blood 85 (1995) 902-911
50. Duda Z. Evaluation of some optimal chemotherapy protocols by using gradient method Appl Math Comp Sci 4 (1994) 257-263
51. Eisen H. Mathematical models in cell biology and cancer chemotherapy (1979), Springer-Verlag, Berlin
52. Ergun A., Camphausen K., and Wein L.M. Optimal scheduling of radiotherapy and angiogenic inhibitors. Bull. Math. Biol. 65 (2003) 407-424
53. Evans N.D., Errington R.J., Shelley M., Feeney G.P., Chapman M.J., Godfrey K.R., Smith P.J., and Chappell M.J. A mathematical model for the in vitro kinetics of the anti-cancer agent topotecan. Math. Biosci. 189 2 (2004) 185-217
54. Faratian D., Goltsov A., Lebedeva G., Sorokin A., Moodie S., Mullen P., Kay C., Um I.H., Langdon S., Goryanin I., and Harrison D.J. Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumab. Cancer Res. 69 16 (2009) 6713-6720
55. Fister K.R., and Panetta J.C. Optimal control applied to cell-cycle-specific cancer chemotherapy. SIAM J. Appl. Math. 60 (2000) 1059-1072
56. Foerster, von J. Some remarks on changing populations. In: Stohlman F. (Ed). Kinetics of Cell Proliferation (1959), Greene & Stratton, New York 382-407
57. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 295 (1971) 1182-1186
58. Folkman J. Antiangiogenesis: new concept for therapy of solid tumors. Ann. Surg. 175 (1972) 409-416
59. Folkman J. Angiogenesis inhibitors generated by tumors. Mol. Med. 1 2 (1995) 120-122
60. Folkman J., and Haudenschild C. Angiogenesis in vitro. Nature 288 (1980) 551-555
61. Folkman J., and Klagsburn M. Angiogenic factors. Science 235 (1987) 442-447
62. Forys U., Kheifetz Y., and Kogan Y. Critical point analysis for three variable cancer angiogenesis models. Math. Biosci. Eng. 2 (2005) 511-525
63. Frieboes H.B., Edgerton M.E., Fruehauf J.P., Rose F.R.A.J., Worrall L.K., Gatenby R.A., Ferrari M., and Cristini V. Prediction of drug response in breast cancer using integrative experimental/computational modeling. Cancer Res. 69 10 (2009) 4484-4492
64. Getto Ph., Kimmel M., and Marciniak-Czochra A. Modelling and analysis of dynamics of viral infection of cells and of interferon resistance. J. Math. Anal. Appl. 344 2 (2008) 821-850
65. Goldie J.H., and Coldman A.J. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat. Rep. 63 (1979) 1727-1733
66. Gompertz B. On nature of the function expressive of the law of human mortality, and a new mode of determining the value of life contingencies. Letter to F. Batly. Esq. Phil. Trans. Roy. Soc. 115 (1825) 513-585
67. Gyllenberg M., and Webb G.F. Quiescence as an explanation of Gompertzian tumor growth. Growth Dev. Aging 53 (1989) 25-33
68. Hahnfeldt P., Panigraphy D., Folkman J., and Hlatky L. Tumor development under angiogenic signaling: a dynamic theory of tumor growth, treatment response and postvascular dormacy. Cancer Res. 59 (1999) 4770-4778
69. Harnevo L.E., and Agur Z. The dynamics of gene amplification described as a multitype compartmental model and as a branching process. Math. Biosci. 103 (1991) 115-138
70. Harnevo L.E., and Agur Z. Drug resistance as a dynamic process in a model for multistep gene amplification under various levels of selection stringency. Cancer Chemother. Pharmacol. 30 (1992) 469-476
71. Harnevo L.E., and Agur Z. Use of mathematical models for understanding the dynamics of gene amplification. Mutat. Res. 292 1 (1993) 17-24
72. Haseltine E.L., Rawlings J.B., and Yin J. Dynamics of viral infections: incorporating both the intracellular and extracellular levels. Comp. Chem. Eng. 29 (2004) 675-686
73. Iwasa Y., Nowak M.A., and Michor F. Evolution of resistance during clonal expansion. Genetics 172 (2006) 2557-2566
74. Jansson B. Simulation of cell cycle kinetics based on a multicompartmental model. Simulation 25 (1975) 99-108
75. Jong, de H. Modeling and simulation of genetic regulatory systems: a literature review. J. Comput. Biol. 9 1 (2002) 67-103
76. Joshi B., Wang X., Banerjee S., Tian H., Matzavinos A., and Chaplain M.A. On immunotherapies and cancer vaccination protocols: a mathematical modelling approach. J. Theor. Biol. 259 4 (2009) 820-827
77. Kaufman R.J., Brown P.C., and Schimke R.T. Loss and stabilization of amplified dihydrofolate reductase genes in mouse sarcoma S-180 cell lines. Mol. Cell. Biol. 1 (1981) 1084-1093
78. Kellen J.A. The reversal of multidrug resistance: an update. J. Exp. Ther. Oncol. 3 (2003) 5-13
79. Kerbel R.S. A cancer therapy resistant to resistance. Nature 390 (1997) 335-340
80. Kerbel R.S. Tumor angiogenesis: past, present and near future. Carcinogenesis 21 (2000) 505-515
81. Kim M., Brahami K., and Woo K.B. A discrete-time model for cell-age, size and DNA distributions of proliferating cells, and its application to the movement of the labeled cohort. IEEE Trans. Biomed. Eng. 21 (1974) 387-399
82. Kim P.S., Lee P.P., and Levy D. Dynamics and potential impact of the immune response to chronic myelogenous leukemia. PLoS Comput. Biol. 4 6 (2008) e1000095 10.1371/journal.pcbi.1000095
83. Kim P.S., Lee P.P., and Levy D. A PDE model for imatinib-treated chronic myelogenous leukemia. Bull. Math. Biol. 70 (2008) 1994-2016
84. Kim P.S., Lee P.P., and Levy D. Modeling imatinib-treated chronic myelogenous leukemia: reducing the complexity of agent-based models. Bull. Math. Biol. 70 (2008) 728-744
85. Kimmel M., and Axelrod D.E. Mathematical models of gene amplification with applications to cellular drug resistance and tumorigenicity. Genetics 125 (1990) 633-644
86. Kimmel M., and Axelrod D.E. Branching Processes in Biology (2002), Springer Verlag, New York, NY
87. Kimmel M., and Stivers D.N. Time-continuous branching walk models of unstable gene amplification. Bull. Math. Biol. 56 (1994) 337-357
88. Kimmel M., and Swierniak A. Control theory approach to cancer chemotherapy: benefiting from phase dependence and overcoming drug resistance. In: Friedman A. (Ed). Tutorials in Mathematical Biosciences III: Cell Cycle, Proliferation, and Cancer. Lecture Notes in Mathematics, Mathematical Biosciences Subseries, 1872 (2006), Springer, Heidelberg 185-222
89. Kimmel M., and Traganos F. Estimation and prediction of cell cycle specific effects of anticancer drugs. Math. Biosci. 80 (1986) 187-208
90. Kimmel M., Axelrod D.E., and Wahl G.M. A branching process model of gene amplification following chromosome breakage. Mutat. Res. 276 3 (1992) 225-239
91. Kimmel M., Swierniak A., and Polanski A. Infinite-dimensional model of evolution of drug resistance of cancer cells. J. Math. Syst. Estim. Contr. 8 1 (1998) 1-16
92. Klagsburn M., and Soker S. VEGF/VPF: the angiogenesis factor found?. Curr. Biol. 3 (1993) 699-702
93. Komarova N.L., and Wodarz D. Drug resistance in cancer: principles of emergence and prevention. Proc. Natl. Acad. Sci. U.S.A. 102 27 (2005) 9714-9719
94. Komarova N.L., and Wodarz D. Effect of cellular quiescence on the success of targeted CML therapy. PLoS ONE 2 10 (2007) e990
95. Konopleva M., Tsao T., Ruvolo P., Stiouf I., Estrov Z., Leysath C.E., Zhao S., Harris D., Chang S., Jackson C.E., Munsell M., Suh N., Gribble G., Honda T., May W.S., Sporn M.B., and Andreef M. Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia. Blood 99 (2002) 326-335
96. Kozusko F., Chen P., Grant S.G., Day B.W., and Panetta J.C. A mathematical model of in vitro cancer cell growth and treatment with the antimitotic agent curacin A. Math. Biosci. 170 1 (2001) 1-16
97. Krishna R., and Mayer L.D. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR in influencing the pharmacokinetics of anticancer drugs. Eur. J. Pharm. Sci. 11 (2000) 265-283
98. Kronik N., Kogan Y., Vainstein V., and Agur Z. Improving alloreactive CTL immunotherapy for malignant gliomas using a simulation model of their interactive dynamics. Cancer Immunol. Immunother. 57 (2008) 425-439
99. Laird A.K. Dynamics of tumor growth. Br. J. Cancer 18 (1964) 490-502
100. Lebowitz J.L., and Rubinow S.I. A theory for the age and generation time distribution of a microbial population. J. Math. Biol. 1 (1974) 17-36
101. Ledzewicz U., and Schaettler H. Optimal bang-bang controls for a 2-compartment model in cancer chemotherapy. J. Optim. Theory Appl. 114 3 (2002) 609-637
102. Ledzewicz U., and Schaettler H. Analysis of a cell-cycle specific model for cancer chemotherapy. J. Biol. Syst. 10 3 (2002) 183-2064
103. Ledzewicz U., and Schaettler H. The influence of PK/PD on the structure of optimal controls in cancer chemotherapy models. Math. Biosci. Eng. 2 (2005) 561-578
104. Ledzewicz U., and Schaettler H. Drug resistance in cancer chemotherapy as an optimal control problem. Discrete Contin. Dyn. Syst. Ser. B 6 1 (2006) 129-150
105. Ledzewicz U., and Schaettler H. Anti-angiogenic therapy in cancer treatment as an optimal control problem. SIAM J. Control Optim. 46 3 (2007) 1052-1079
106. Ledzewicz U., and Schaettler H. Model of maximizing bone marrow with pharmacokinetics. Math. Biosci. 206 2 (2007) 320-342
107. Ledzewicz U., and Schaettler H. Optimal and suboptimal protocols for a class of mathematical models of tumor anti-angiogenesis. J. Theor. Biol. 252 (2008) 295-312
108. Ledzewicz U., Schattler H., and Swierniak A. Finite dimensional models of drug resistance and phase specificity. J. Med. Inf. Technol. 8 (2004) IP5-IP13
109. Levi F., and Schibler U. Circadian rhythms: mechanisms and therapeutic implications. Ann. Rev. Pharmacol. Toxicol. 47 (2007) 593-628
110. Lieschke G.J., Stanley E., Grail D., Hodgson G., Sinickas V., Gall J.A., Sinclair R.A., and Dunn A.R. Mice lacking both macrophage- and granulocyte-macrophage colony-stimulating factor have macrophages and coexistent osteopetrosis and severe lung disease. Blood 84 (1994) 27-35
111. Lipniacki T., Paszek P., Marciniak-Czochra A., Brasier A.R., and Kimmel M. Transcriptional stochasticity in gene expression. J. Theor. Biol. 238 (2006) 348-367
112. Lipniacki T., Puszynski K., Paszek P., Brasie A.R., and Kimmel M. Single TNFalpha trimers mediating NF-kappaB activation: stochastic robustness of NF-kappaB signaling. BMC Bioinformatics 8 (2007) 376 10.1186/1471-2105-8-376
113. Liscovitch M., and Lavie Y. Cancer multidrug resistance: a review of recent drug discovery research. Idrugs 5 (2002) 349-355
114. Liscovitch M., and Lavie Y. Cancer multidrug resistance: a review of recent drug discovery research. Idrugs 5 (2002) 349-355
115. Liu F., Poursine-Laurent J., and Link D.C. The granulocyte colony-stimulating factor receptor is required for the mobilization of murine hematopoietic progenitors into peripheral blood by cyclophosphamide or interleukin-8 but not flt-3 ligand. Blood 90 (1997) 2522-2528
116. Mantzaris N.V., Webb S., and Othmer H.G. Mathematical modeling of tumor-induced angiogenesis. J. Math. Biol. 49 (2004) 111-127
117. Marciniak-Czochra A., and Kimmel M. Modelling of early lung cancer progression: influence of growth factor production and cooperation between partially transformed cells. Math. Models Methods Appl. Sci. 17 (2007) 1693-1719 suppl
118. Marciniak-Czochra A., and Kimmel M. Reaction-diffusion model of early carcinogenesis: the effects of influx of mutated cells. Math. Model Nat. Phenom. 3 7 (2008) 90-114
119. Marciniak-Czochra A., and Ptashnyk M. Derivation of a macroscopic receptor-based model using homogenization techniques. SIAM J. Math. Anal. 40 1 (2008) 215-237
120. Martin R.B. Optimal control drug scheduling of cancer chemotherapy. Automatica 28 (1992) 1113-1123
121. Merino V., Jimenez-Torres N.V., and Merino-Sanjuan M. Relevance of multidrug resistance proteins on the clinical efficacy of cancer therapy. Curr. Drug Deliv. 1 3 (2004) 203-212
122. Michor F. Mathematical models of cancer stem cells. J. Clin. Oncol. 26 17 (2008) 2854-2861
123. Michor F., Hughes T.P., Iwasa Y., Branford S., Shah N.P., Sawyers C.L., and Nowak M.A. Dynamics of chronic myeloid leukaemia. Nature 435 (2005) 1267-1270
124. Michor F., Nowak M.A., and Iwasa Y. Evolution of resistance to cancer therapy. Curr. Pharm. Des. 12 (2006) 261-271
125. Mohler R.R. Bilinear Control Processes with Applications to Engineering, Ecology and Medicine (1973), Academic Press, New York, NY
126. Moschos S.M., Lesinski G.B., Carson III G.B., and Kirkwood J.M. The type I interferon system with emphasis on its role in malignancies: interferons are more than "antivirals". In: Caligiuri M.A., and Lotze M.T. (Eds). Cytokines in the Genesis and Treatment of Cancers (2007), Humana Press, Totowa, NJ 339-372
127. Murray J.M. Optimal control for a cancer chemotherapy problem with general growth and loss functions. Math. Biosci. 98 (1990) 273-287
128. Oklejewicz M., Destici E., Tamanini F., Hut R.A., Janssens R., and Horst van der G.T. Phase resetting of the mammalian circadian clock by DNA damage. Curr. Biol. 18 (2008) 286-291
129. Ozben T. Mechanisms and strategies to overcome multiple drug resistance in cancer. FEBS Lett. 580 12 (2006) 2903-2909
130. Paiva L.R., Binny C., Ferreira Jr. S.C., and Martins M.L. A multiscale mathematical model for oncolytic virotherapy. Cancer Res. 69 3 (2009) 1205-1211
131. Panetta J.C. A mathematical model of drug resistance: heterogeneous tumors. Math. Biosci. 147 (1998) 41-61
132. Panetta J.C., Schaiquevich P., Santana V.M., and Stewart C.F. Using pharmacokinetic and pharmacodynamics modeling and simulation to evaluate importance of schedule in topotecan therapy for pediatric neuroblastoma. Clin. Cancer Res. 14 1 (2008) 318-325
133. Paszek P. Modeling stochasticity in gene regulation: characterization in the terms of the underlying distribution function. Bull. Math. Biol. 69 (2007) 1567-1601
134. Pontryagin L.S., Boltyanski V.G., Gamkrelidze R.V., and Mischenko E.F. Mathematical Theory of Optimal Processes (1962), Wiley, New York, NY
135. Puszynski K., Bertolusso R., and Lipniacki T. Crosstalk between p53 and NF-κB systems: pro- and anti-apoptotic functions of NF-κB. IET Sys. Biol. 3 5 (2009) 356-367
136. Raj A., Peskin C.S., Tranchina D., Vargas D.Y., and Tyagi S. Stochastic mRNA synthesis in mammalian cells. PLoS Biol. 4 10 (2006) e309 10.1371/journal.pbio.0040309
137. Roeder I., Horn M., Glauche I., Hochhaus A., Mueller M.C., and Loeffler M. Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nat. Med. 10 (2006) 1181-1184
138. Roose T., Chapman S.J., and Maini P.K. Mathematical models of avascular tumor growth. SIAM Rev. 49 2 (2007) 179-208
139. Roskelley C.D., and Bissell M.J. The dominance of the microenvironment in breast and ovarian cancer. Cancer Biol. 12 (2002) 97-104
140. Sanga S., Sinek J.P., Frieboes H.B., Ferrari M., Fruehauf J.P., and Cristini V. Mathematical modeling of cancer progression and response to chemotherapy. Expert Rev. Anticancer Ther. 6 10 (2006) 1361-1376
141. Shackney S.E., and Shankey T.V. Cell cycle models for molecular biology and molecular oncology: exploring new dimensions. Cytometry 35 2 (1999) 97-116
142. Shochat E., and Rom-Kedar V. Novel strategies for granulocyte colony-stimulating factor treatment of severe prolonged neutropenia suggested by mathematical modeling. Clin. Cancer Res. 14 20 (2008) 6354-6363
143. Smieja J. Drug resistance in cancer models. In: Wai-Yuan T., and Hannin L. (Eds). Handbook of Cancer Models with Application to Cancer Screening, Cancer Treatment and Risk Assessment. World Sci. (2008) 425-456
144. Smieja J., and Swierniak A. Different models of chemotherapy taking into account drug resistance stemming from gene amplification. Int. J. Appl. Math. Comput. Sci. 13 (2003) 297-306
145. Smieja J., Swierniak A., and Duda Z. Gradient method for finding optimal scheduling in infinite dimensional models of chemotherapy. J. Theor. Med. 3 (2001) 25-36
146. Smieja J., Jamalludin M., Brasier A.R., and Kimmel M. Model-based analysis of Interferon-β induced signaling pathway. Bioinformatics 24 20 (2008) 2363-2369
147. Smith G.P. Evolution of repeated DNA sequences by unequal crossover. Science 191 (1976) 528-535
148. Speer J.F., Petrosky V.E., Retsky M.W., and Wardwell R.H. A stochastic numerical model of breast cancer growth that simulates clinical data. Cancer Res. 44 (1984) 4124-4130
149. Stark G.R. Regulation and mechanisms of mammalian gene amplification. Adv. Cancer Res. 61 (1993) 87-113
150. Sullivan P.W., and Salmon S.E. Kinetics of tumor growth and regression in IgG multiple myeloma. J. Clin. Invest. 51 (1972) 1697-1708
151. Sultana T.A., Harada H., Ito K., Tanaka H., Kyo T., and Kimura A. Expression and functional analysis of granulocyte colony-stimulating factor receptors on CD34++ cells in patients with myelodysplastic syndrome (MDS) and MDS-acute myeloid leukaemia. Br. J. Haematol. 121 (2003) 63-75
152. Swan G.W. Optimal control applications in the chemotherapy of multiple myeloma. J. Math. Appl. Med. Biol. 2 (1985) 139-160
153. Swan G.W. Cancer chemotherapy optimal control using the Verhulst-Pearl equation. Bull. Math. Biol. 48 (1986) 381-404
154. Swan G.W. Role of optimal control theory in cancer chemotherapy. Math. Biosci. 101 (1990) 237-284
155. Swan G.W., and Vincent T.L. Optimal control analysis in the chemotherapy of IgG multiple myeloma. Bull. Math. Biol. 39 (1977) 317-337
156. Swierniak A. Optimal treatment protocols in leukemia-modeling the proliferation cycle. Trans. IMACS Sci. Comp. 5 (1989) 51-53
157. Swierniak A. Cell cycle as an object of control. J. Biol. Syst. 3 (1995) 41-54
158. Swierniak A. Direct and indirect control of cancer populations. Bull. Polish Acad. Sci., Technical Sciences 56 4 (2008) 367-378
159. Swierniak, A., 2009. Comparison of six models of antiangiogenic therapy. Applicationes Mathematicae 36 (3), 333-348.
160. Swierniak A., and Duda Z. Some control problems related to optimal chemotherapy-singular solutions. J. Appl. Math. Comput. Sci. 2 (1992) 293-302
161. Swierniak A., and Duda Z. Singularity of optimal control problems arising in cancer chemotherapy. Math. Comput. Model. 19 (1994) 255-262
162. Swierniak A., and Kimmel M. Optimal control application to leukemia chemotherapy protocols design. ZN Pol.Sl., S. Aut. 74 (1984) 261-277 in Polish
163. Swierniak A., and Polanski A. Irregularity of optimal control problem in scheduling of cancer chemotherapy. J. Appl. Math. Comp. Sci. 4 (1994) 263-271
164. Swierniak A., and Smieja J. Analysis and optimization of drug resistant and phase specific cancer chemotherapy. Math. Biosci. Eng. 2 (2005) 650-670
165. Swierniak A., Polanski A., and Kimmel M. Optimal control problems arising in cell-cycle-specific cancer chemotherapy. Cell Prolif. 29 3 (1996) 117-139
166. Swierniak A., Polanski A., Kimmel M., Bobrowski A., and Smieja J. Qualitative analysis of controlled drug resistance model-inverse Laplace and semigroup approach. Control Cybern. 28 1 (1999) 61-75
167. Swierniak A., Ledzewicz U., and Schaettler H. Optimal control for a class of compartmental models in cancer chemotherapy. Int. J. Appl. Math. Comput. Sci. 13 3 (2003) 357-368
168. Swierniak A., Polanski A., Smieja J., and Kimmel M. Modeling growth of drug resistant cancer populations as system with positive feedback. Math. Comput. Model. 37 (2003) 1245-1252
169. Szakacs G., Paterson J.K., Ludwig J.A., Booth-Genthe C., and Gottesman M.M. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 5 3 (2006) 219-234
170. Tafuri A., and Andreeff M. Kinetic rationale for cytokine-induced recruitment of myeloblastic leukemia followed by cycle-specific chemotherapy in vitro. Leukemia 4 (1990) 826-834
171. Takahashi M. Theoretical basis for cell cycle analysis. Part I. J. Theor. Biol. 13 (1966) 203-211
172. Takahashi M. Theoretical basis for cell cycle analysis, Part II. J. Theor. Biol. 15 (1968) 195-209
173. Takemura Y., Kobayashi H., and Miyachi H. Cellular and molecular mechanisms of resistance to antifolate drugs: new analogues and approaches to overcome the resistance. Int. J. Hematol. 66 4 (1997) 459-477
174. Tarnawski R., Skladowski K., Swierniak A., Wygoda A., and Mucha A. Repopulation of the tumor cells during radiotherapy is doubled during treatment gaps. J. Theor. Med. 2 4 (2000) 297-305
175. Thames H.D., and Hendry J.H. Fractionation in Radiotherapy (1987), Taylor&Francis, London
176. Venkatasubramanian R., Henson M.A., and Forbes N.S. Integrating cell-cycle progression, drug penetration and energy metabolism to identify improved cancer therapeutic strategies. J. Theor. Biol. 253 (2008) 98-117
177. Vose J.M., and Armitage J.O. Clinical applications of hematopoietic growth factors. J. Clin. Oncol. 13 (1995) 1023-1035
178. Webb G.F. Theory of Nonlinear Age Dependent Population Dynamics (1985), Marcel Dekker, New York, NY
179. Webb G.F. Resonance phenomena cell population chemotherapy models. Rocky Mountain J. Math. 20 (1990) 1195-1216
180. Weidner N. Intratumor microvessel density as a prognostic factor in cancer. Am. J. Pathol. 147 1 (1995) 9-19
181. Wheldon T.E. Mathematical Models in Cancer Chemotherapy (1988), Medical Sci, Series, Hilger, Bristol
182. Wilkinson D.J. Stochastic Modelling for Systems Biology (2006), Chapman & Hall/CRC, Boca Raton, FL
183. Windle B., and Wahl G.M. Molecular dissection of mammalian gene amplification: new mechanistic insights revealed by analysis of very early events. Mutat. Res. 276 3 (1992) 199-224
184. Windle B., Draper B.W., Yin Y., O'Gorman S., and Wahl G.M. A central role for chromosome breakage in gene amplification, deletion, formation, and amplicon integration. Genes Dev. 5 (1991) 160-174
185. Wodarz D., and Komarova N. Towards predictive computational models of oncolytic virus therapy: basis for experimental validation and model selection. PLoS ONE 4 1 (2009) e4271
186. Zi Z., Cho K.-H., Sung M.-H., Xia X., Zheng J., and Sun Z. In silico identification of the key components and steps in IFN-γ induced JAK-STAT signaling pathway. FEBS Lett. 579 (2005) 1101-1108
187. Zietz S., and Nicolini C. Mathematical approaches to optimization of cancer chemotherapy. Bull. Math. Biol. 41 (1979) 305-324